Last updated: September 7, 2026
Alcaftadine is a topical ophthalmic antihistamine marketed primarily as Lastacaft for the prevention of itching associated with allergic conjunctivitis. Its commercial trajectory shifted from a branded prescription product to an over-the-counter allergy-eye-care product after FDA approval of the nonprescription switch. The market is mature, competitive, and heavily influenced by generic availability, retail distribution, seasonal allergy demand, and competition from ketotifen and olopatadine products.
AbbVie, through its acquisition of Allergan, controls the Lastacaft brand. Public filings do not report standalone revenue, profitability, or unit sales for alcaftadine. Financial analysis therefore depends on product positioning, regulatory milestones, market structure, and AbbVie’s broader ophthalmology disclosures rather than a separately reported income statement.
What is alcaftadine and how is it marketed?
Alcaftadine is a selective histamine H1-receptor antagonist formulated as an ophthalmic solution. The marketed product is Lastacaft ophthalmic solution, 0.25%, indicated for the prevention of itching associated with allergic conjunctivitis.
| Attribute |
Detail |
| Active ingredient |
Alcaftadine |
| Dosage form |
Ophthalmic solution |
| Strength |
0.25% |
| Brand |
Lastacaft |
| Original sponsor |
Allergan |
| Current corporate owner |
AbbVie, following its acquisition of Allergan |
| FDA product type |
Ophthalmic antihistamine |
| Original U.S. approval |
2010 |
| Primary indication |
Prevention of itching associated with allergic conjunctivitis |
| Commercial channel |
Prescription initially; over-the-counter retail channel after switch |
| Principal competitors |
Pataday, Zaditor, Alaway, generic olopatadine, generic ketotifen |
The product is used for seasonal allergic conjunctivitis and related ocular allergy symptoms. Its value proposition is once-daily dosing and a nonprescription positioning that allows direct consumer purchase.
When did alcaftadine receive FDA approval?
The FDA approved Lastacaft in 2010 under New Drug Application 022134 for the prevention of itching associated with allergic conjunctivitis. The original product was a prescription ophthalmic solution.
The FDA later approved the switch of Lastacaft from prescription to over-the-counter status. This changed the commercial model from physician-mediated prescribing to consumer self-selection through pharmacies, mass retailers, e-commerce channels, and eye-care aisles.
Key FDA milestones
| Year |
Regulatory milestone |
Commercial significance |
| 2010 |
FDA approval of Lastacaft 0.25% ophthalmic solution |
Established alcaftadine as a branded prescription therapy |
| 2011 |
Prescription commercial launch |
Initiated physician-directed sales |
| 2021 |
FDA approval of nonprescription switch |
Expanded access to retail consumers |
| 2022 onward |
OTC commercialization |
Increased exposure to retail competition and consumer marketing |
The prescription-to-OTC transition reduced dependence on reimbursement and physician prescribing. It also changed the competitive benchmark. Lastacaft increasingly competes with consumer-facing brands such as Pataday and store-brand versions of olopatadine and ketotifen.
What is the financial trajectory of alcaftadine?
Alcaftadine’s public financial trajectory cannot be quantified from AbbVie’s reported segment disclosures because AbbVie does not separately report Lastacaft revenue. The product is included within broader pharmaceutical or eye-care commercial activity.
The economic profile has likely changed across three stages:
- Prescription launch and adoption: Revenue depended on ophthalmologist prescribing, formulary access, promotional activity, and branded prescription pricing.
- Mature prescription competition: Generic and branded alternatives limited pricing power and required continued commercial support.
- OTC transition: Revenue shifted toward retail sell-through, shelf placement, seasonal demand, consumer advertising, and retailer margins.
The OTC model can increase unit access but does not guarantee higher manufacturer revenue. A prescription product may generate higher revenue per unit through branded pricing, while an OTC product can reach a larger consumer population at lower net prices.
Financial trajectory by commercial phase
| Phase |
Revenue driver |
Main constraint |
Expected margin pressure |
| Prescription launch |
Physician adoption and branded prescriptions |
Limited diagnosis and prescribing volume |
Moderate |
| Mature prescription market |
Repeat prescriptions and allergy season |
Generic and branded substitutes |
High |
| OTC retail period |
Consumer awareness, retail distribution, shelf position |
Private-label products and promotional pricing |
High |
| Long-term mature OTC market |
Brand loyalty and seasonal repeat use |
Category commoditization |
High |
A precise revenue estimate would require proprietary prescription, retail scanner, or company-level product data. AbbVie’s public annual reports do not provide a Lastacaft-specific revenue line.
How large is the alcaftadine market?
Alcaftadine participates in the U.S. allergic-eye-disease market, a subsegment of ophthalmic pharmaceuticals and consumer health products. The relevant market includes:
- Olopatadine ophthalmic products, including Pataday and generics
- Ketotifen products, including Zaditor, Alaway, and generics
- Prescription antihistamine and mast-cell stabilizer products
- Artificial tears and combination allergy-relief products
- Physician-administered or prescription therapies for more severe ocular allergy
The OTC ocular-allergy segment is seasonal. Demand rises during periods of high pollen exposure and varies by geography, weather, consumer behavior, and allergy prevalence. Sales typically depend more on retail volume and marketing execution than on a durable reimbursement advantage.
Alcaftadine is unlikely to hold category-wide leadership because olopatadine and ketotifen have broader brand recognition, extensive generic availability, and established retail distribution. Lastacaft’s commercial position depends on differentiated consumer messaging, once-daily convenience, brand recognition, and AbbVie’s distribution capabilities.
How does Lastacaft compare with Pataday, Zaditor, and Alaway?
| Product |
Active ingredient |
Typical dosing profile |
Market position |
| Lastacaft |
Alcaftadine 0.25% |
Once daily |
Branded OTC allergy-eye product |
| Pataday |
Olopatadine |
Once daily, depending on product |
Major branded OTC and prescription competitor |
| Zaditor |
Ketotifen |
Twice daily in common OTC use |
Established OTC allergy-eye product |
| Alaway |
Ketotifen |
Twice daily in common OTC use |
Established retail and pharmacy brand |
| Store-brand products |
Usually olopatadine or ketotifen |
Product-specific |
Price-led competition |
Pataday has a strong competitive advantage because olopatadine has substantial clinical familiarity, multiple approved formulations, and broad generic penetration. Ketotifen products compete on price and established consumer recognition.
Lastacaft’s strongest commercial differentiators are once-daily dosing and a brand-specific product identity. Its weaknesses are limited molecule-level differentiation, a crowded OTC category, and the availability of lower-priced alternatives.
What patents protect alcaftadine and Lastacaft?
The original alcaftadine product was protected by pharmaceutical patents, formulation claims, and regulatory exclusivity associated with the branded product. However, the commercial significance of the original patent estate has declined because the product is more than a decade past its initial FDA approval and has entered a mature competitive market.
Patent protection for a drug such as alcaftadine may include:
- Composition-of-matter claims covering the active molecule
- Ophthalmic formulation claims
- Concentration and vehicle claims
- Stabilizer or preservative claims
- Method-of-use claims for allergic conjunctivitis
- Manufacturing or purification claims
- Pediatric or dosing-related exclusivity
The most commercially relevant question is whether enforceable Orange Book-listed patents continue to block or delay generic alcaftadine ophthalmic products. That determination depends on current FDA Orange Book listings, patent expiration dates, terminal disclaimers, pediatric extensions, and any litigation or settlement agreements.
A current patent-by-patent conclusion cannot be made from the public commercial information identified here. The original composition-of-matter and early product patents would generally be expected to have expired or approached expiration given the 2010 approval date, while later formulation or use patents could have different terms.
What is the Orange Book status of alcaftadine?
Lastacaft was approved through the FDA’s prescription-drug pathway and was therefore eligible for Orange Book listing during its prescription period. The relevance of Orange Book patents changed after the product’s switch to OTC status.
Orange Book issues affecting alcaftadine include:
- Whether the original NDA remains listed as an active prescription NDA
- Whether patents remain listed against NDA 022134
- Whether generic applicants filed Abbreviated New Drug Applications before or after the OTC switch
- Whether an OTC product can be marketed under a separate regulatory strategy
- Whether branded and generic versions are therapeutically equivalent
- Whether any remaining listed patents cover the marketed formulation rather than the active ingredient
The OTC switch does not automatically eliminate all intellectual-property rights. It does, however, change the regulatory and commercial pathway for competing products. Generic prescription competition and direct OTC competition can develop under different approval and labeling structures.
Have companies filed Paragraph IV challenges against alcaftadine?
A Paragraph IV challenge would assert that one or more listed patents are invalid, unenforceable, or not infringed. Publicly available commercial information does not establish a major, publicly documented Paragraph IV litigation campaign involving alcaftadine comparable to challenges against high-revenue specialty drugs.
The absence of a prominent litigation record is commercially consistent with a smaller ophthalmic product whose market opportunity may not justify extensive patent litigation costs. Generic manufacturers may instead enter after relevant patent barriers expire or pursue regulatory routes that do not create significant branded litigation exposure.
Potential generic-entry triggers include:
- Expiration of remaining listed patents
- FDA approval of an ANDA
- Patent settlement or license
- OTC regulatory approval for an equivalent product
- Commercial decision to launch at risk
- Market demand sufficient to support manufacturing and distribution
What generic entry risks exist for Lastacaft?
Generic and private-label risk is high. The active ingredient is a small-molecule antihistamine, the dosage form is a conventional ophthalmic solution, and the product has a long commercial history. These factors generally reduce technical barriers compared with complex biologics, sustained-release implants, or device-dependent ophthalmic products.
Key generic-entry risks include:
| Risk |
Effect on Lastacaft |
| Generic alcaftadine solution |
Erodes prescription and professional-channel pricing |
| Generic olopatadine |
Limits the category’s overall price ceiling |
| Generic ketotifen |
Provides a low-cost substitute |
| Store-brand OTC products |
Pressures retail pricing and shelf space |
| Retailer private label |
Reduces brand conversion and repeat purchase |
| Seasonal promotional discounting |
Compresses manufacturer and retailer margins |
| Low switching costs |
Makes consumer loyalty difficult to sustain |
A generic launch would likely affect price before it eliminates the brand. Lastacaft could retain demand among consumers who value brand recognition, prior experience, or product availability. The financial impact would depend on whether the generic enters prescription channels, OTC channels, or both.
How strong is the alcaftadine patent estate?
The patent estate appears commercially weaker today than during the product’s launch period because the active ingredient and product have been marketed for more than a decade. The likely strengths are formulation know-how, regulatory history, manufacturing controls, and brand recognition rather than broad exclusionary patent coverage.
Patent-strength assessment
| Factor |
Assessment |
| Composition-of-matter protection |
Likely mature or expired based on approval timing |
| Formulation protection |
Potentially relevant but narrower |
| Method-of-use protection |
Limited value in a crowded allergy indication |
| Manufacturing protection |
May create operational barriers but rarely blocks all competitors |
| Regulatory data package |
More valuable during the prescription period |
| Brand and trade dress |
Relevant in OTC retail competition |
| Switching costs |
Low |
| Biosimilar protection |
Not applicable |
The most durable assets are likely the Lastacaft name, consumer awareness, distribution relationships, and manufacturing consistency. These are commercial advantages rather than strong molecule-level barriers.
Does biosimilar risk affect alcaftadine?
No. Alcaftadine is a small-molecule ophthalmic drug, not a biologic. Biosimilar pathways under the Public Health Service Act do not apply.
The relevant competitive risks are generic substitution, abbreviated new drug applications, OTC monograph or NDA-based competition, private-label products, and brand substitution within the ocular-allergy category.
What licensing deals affect alcaftadine?
The principal corporate transaction affecting alcaftadine is AbbVie’s acquisition of Allergan, completed in 2020. Lastacaft became part of AbbVie’s acquired commercial portfolio.
No major publicly disclosed out-licensing transaction is established as the central driver of alcaftadine commercialization. The product’s economics are primarily tied to ownership of the brand, manufacturing arrangements, retail distribution, and portfolio management.
The Allergan transaction gave AbbVie control of:
- Lastacaft commercialization
- Associated trademarks and product know-how
- Regulatory records and manufacturing relationships
- Existing distribution and commercial infrastructure
What litigation and settlement risks affect Lastacaft?
The available commercial record does not identify a major ongoing patent litigation campaign that materially changes the product’s outlook. The more immediate risks are commercial rather than legal:
- Challenges to patent validity or listing status
- Generic or private-label competition
- Trademark or trade-dress disputes in OTC retail
- Product-liability claims
- Manufacturing and supply interruptions
- Promotional claims disputes
- Retailer and distributor contract changes
A settlement with a generic manufacturer could accelerate market entry while preserving some branded revenue. Without a confirmed settlement record, no specific entry date or economic terms should be assigned.
What manufacturing and intellectual-property barriers exist?
Alcaftadine ophthalmic solution is less technically difficult to manufacture than sterile injectable biologics, but ophthalmic production still requires validated sterile manufacturing, container-closure controls, preservative management, particulate control, and stability data.
Potential barriers include:
- Sterile filling capacity
- Validated ophthalmic manufacturing lines
- Container compatibility
- Preservative and pH control
- Stability across the labeled shelf life
- FDA facility compliance
- Supply of active pharmaceutical ingredient
- Packaging suitable for OTC retail distribution
These barriers can delay entry but are unlikely to create a durable monopoly if market demand supports multiple manufacturers.
What is the outlook for alcaftadine revenue?
The base-case outlook is mature to declining branded revenue, offset by potential volume growth from OTC distribution. The most likely pattern is:
- Stable or declining prescription revenue
- Higher consumer reach after the OTC switch
- Continued seasonal volume fluctuations
- Lower net price per unit than during the prescription period
- Increased retailer and promotional costs
- Margin pressure from branded and private-label alternatives
Upside would come from strong consumer recognition, effective allergy-season advertising, superior retail placement, and sustained preference for once-daily dosing. Downside would come from generic alcaftadine entry, retailer substitution, aggressive Pataday promotions, and consumer migration to lower-cost olopatadine or ketotifen products.
Key Takeaways
- Alcaftadine is marketed as Lastacaft, an ophthalmic antihistamine for allergic-eye itching.
- FDA approval occurred in 2010, followed by a prescription-to-OTC switch in the early 2020s.
- AbbVie owns the product through its acquisition of Allergan.
- Standalone Lastacaft revenue is not separately disclosed in AbbVie’s public financial reporting.
- The commercial market is mature and highly competitive, with Pataday, Zaditor, Alaway, olopatadine, ketotifen, and private-label products.
- Generic and OTC substitution risks are high because alcaftadine is a small-molecule ophthalmic solution with low switching costs.
- Biosimilar risk does not apply.
- The product’s remaining value is more dependent on brand, distribution, retail placement, and consumer recognition than on broad patent exclusivity.
- Financial performance is likely to depend on OTC volume growth offsetting lower pricing and higher retail competition.
- A current patent-expiration and Paragraph IV analysis requires the active FDA Orange Book and federal court records for the relevant NDA and patents.
FAQs
Is alcaftadine the same as Lastacaft?
Yes. Alcaftadine is the active ingredient in Lastacaft ophthalmic solution 0.25%.
Is Lastacaft available without a prescription?
The FDA approved a nonprescription switch for Lastacaft, allowing OTC commercialization in the United States.
Is alcaftadine better than olopatadine?
Neither product has a universal clinical advantage for all patients. Both are topical ophthalmic antihistamines used for allergic-eye symptoms, while dosing, tolerability, price, and availability influence product selection.
Can a generic manufacturer make alcaftadine eye drops?
A manufacturer may pursue an approved generic or other permitted regulatory pathway, subject to FDA requirements, patent status, formulation equivalence, manufacturing controls, and market economics.
Does AbbVie disclose Lastacaft sales separately?
No. AbbVie’s public financial reporting does not generally provide a standalone Lastacaft revenue line.
References
- U.S. Food and Drug Administration. (2010). Lastacaft (alcaftadine ophthalmic solution) prescribing information.
- U.S. Food and Drug Administration. (2021). FDA approves switch of Lastacaft ophthalmic solution to over-the-counter status.
- AbbVie Inc. (2020). AbbVie completes acquisition of Allergan.
- AbbVie Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
